Ocular Melanoma Foundation
Ocular Melanoma Foundation is a company.
Active
Updated: ·
Financial History
Total Raised
N/A
Valuation
N/A
Leadership Team
Key people at Ocular Melanoma Foundation.
Ocular Melanoma Foundation is a company.
Key people at Ocular Melanoma Foundation.
Key people at Ocular Melanoma Foundation.
The Ocular Melanoma Foundation (OMF) is a 501(c)(3) nonprofit organization, not a for-profit company, dedicated to combating ocular melanoma—a rare eye cancer affecting about 7 in a million people annually.[1][6][7] Its mission centers on accelerating scientific research, advocacy, and awareness while providing education and support to patients, families, and healthcare professionals; OMF raises funds, partners with researchers and other cancer organizations, and has amassed over $4 million to fund research toward a cure.[1][2][6] As the leading resource for eye cancer research funding and patient support, OMF serves as a critical first stop for newly diagnosed individuals, emphasizing translation of discoveries into treatments and advocacy within the broader melanoma community.[1][2]
OMF was founded in 2003 by Grant Allen and Dr. Robert C. Allen, a renowned glaucoma specialist, Chairman of Ophthalmology at VCU/Medical College of Virginia, and an ocular melanoma patient himself.[2] Motivated by the scarcity of up-to-date treatment information and research for this rare disease, the duo established OMF as a small, entrepreneurial nonprofit based in Washington, DC.[1][2] Early efforts focused on filling these gaps, evolving into a pivotal force that has funded over $3–4 million in research while building partnerships with academicians, clinicians, and other cancer foundations.[2][6]
While not a tech entity, OMF intersects the biotech and medtech ecosystem by fueling innovation in oncology, particularly for rare cancers where market forces alone underinvest.[6] It rides trends in precision medicine and immunotherapy—evident in funded trials like tebentafusp (T-cell engaging therapy) and bel-sar (light-activated tumor necrosis)—addressing unmet needs in a disease with no metastatic cure and high liver metastasis rates (~85%).[6][7] Timing aligns with rising NCI funding for collaborative groups like COOG and growing awareness via nonprofits, influencing biotech startups and pharma (e.g., Aura Biosciences) to prioritize OM, thus expanding the rare disease research pipeline.[3][6]
OMF's trajectory points to expanded trial funding and partnerships amid immunotherapy breakthroughs, potentially driving first-line treatments for metastatic OM and early-stage interventions.[6] Trends like AI-driven genetic testing for prognosis and novel targeted therapies will shape its work, amplifying influence through collaborations with emerging biotech firms. As the go-to hub for a niche with 7,000 global annual diagnoses, OMF remains essential in bridging research gaps to deliver the long-sought cure.[7]
